A Small-molecule Antagonist Radiotracer for Positron Emission Tomography Imaging of the Mu Opioid Receptor

Insights

Researchers developed novel non-agonist ligands for the mu opioid receptor, offering a safer alternative for studying the opioid system and its role in the opioid crisis. These new ligands show potential for reduced respiratory depression risk.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Radiochemistry

Background:

  • The opioid crisis stems from opioid misuse, often targeting the mu opioid receptor.
  • Existing mu opioid receptor radioligands face strict regulation due to abuse and respiratory depression risks.

Purpose of the Study:

  • To design and characterize novel non-agonist ligands for the mu opioid receptor.
  • To evaluate ligands for binding affinity, intrinsic activity, and blood-brain barrier permeability.
  • To develop safer radioligands for studying the endogenous opioid system.

Main Methods:

  • Synthesis and evaluation of 24 non-agonist ligands for mu opioid receptor.
  • Assessment of binding affinity, selectivity (vs. delta and kappa opioid receptors), and intrinsic activity.
  • Preparation of a novel radiotracer, [11C]1A, using metallophotoredox.
  • In vivo brain uptake studies in rhesus macaques.

Main Results:

  • Several ligands exhibited single-digit nM binding affinity and selectivity for the mu opioid receptor.
  • Ligands 1A and 3A demonstrated antagonist behavior, suggesting reduced respiratory depression potential.
  • [11C]1A showed brain uptake and accumulation in the caudate and putamen in vivo.
  • Naloxone partially displaced [11C]1A binding, indicating target engagement.

Conclusions:

  • GSK1521498 and related compounds are suitable for radioligand development.
  • These novel ligands offer a safer approach to investigating opioid neurobiology.
  • The developed radiotracer enables safer interrogation of the endogenous opioid system.